{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T23:27:51Z","timestamp":1793662071151,"version":"4.5.1"},"reference-count":24,"publisher":"American Diabetes Association","issue":"8","license":[{"start":{"date-parts":[[2021,8,27]],"date-time":"2021-08-27T00:00:00Z","timestamp":1630022400000},"content-version":"vor","delay-in-days":4103,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/3.0\/"}],"content-domain":{"domain":["diabetesjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2010,8,1]]},"abstract":"<jats:sec>\n                  <jats:title>OBJECTIVE<\/jats:title>\n                  <jats:p>To investigate the associations of plasma levels of soluble receptor for advanced glycation end products (sRAGE) with incident cardiovascular disease (CVD) and all-cause mortality in type 1 diabetes and the extent to which any such associations could be explained by endothelial and renal dysfunction, low-grade inflammation, arterial stiffness, and advanced glycation end products (AGEs).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>RESEARCH DESIGN AND METHODS<\/jats:title>\n                  <jats:p>We prospectively followed 169 individuals with diabetic nephropathy and 170 individuals with persistent normoalbuminuria who were free of CVD at study entry and in whom levels of sRAGE and other biomarkers were measured at baseline. The median follow-up duration was 12.3 years (7.6\u201312.5).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>RESULTS<\/jats:title>\n                  <jats:p>The incidence of fatal and nonfatal CVD and all-cause mortality increased with higher baseline levels of log-transformed sRAGE (Ln-sRAGE) independently of other CVD risk factors: hazard ratio (HR) 1.90 (95% CI 1.13\u20133.21) and 2.12 (1.26\u20133.57) per 1-unit increase in Ln-sRAGE, respectively. Adjustments for estimated glomerular filtration rate (eGFRMDRD), but not or to a smaller extent for markers of endothelial dysfunction, low-grade inflammation, arterial stiffness, and AGEs, attenuated these associations to HR 1.59 (95% CI 0.91\u20132.77) for fatal and nonfatal CVD events and to 1.90 (1.09\u20133.31) for all-cause mortality. In addition, in patients with nephropathy, the rate of decline of GFR was 1.38 ml\/min\/1.73 m2 per year greater per 1-unit increase of Ln-sRAGE at baseline (P = 0.036).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>CONCLUSIONS<\/jats:title>\n                  <jats:p>Higher levels of sRAGE are associated with incident fatal and nonfatal CVD and all-cause mortality in individuals with type 1 diabetes. sRAGE-associated renal dysfunction may partially explain this association.<\/jats:p>\n               <\/jats:sec>","DOI":"10.2337\/db09-1509","type":"journal-article","created":{"date-parts":[[2010,6,4]],"date-time":"2010-06-04T02:24:48Z","timestamp":1275618288000},"page":"2027-2032","update-policy":"https:\/\/doi.org\/10.2337\/ada-journal-policies","source":"Crossref","is-referenced-by-count":108,"title":["Higher Plasma Soluble Receptor for Advanced Glycation End Products (sRAGE) Levels Are Associated With Incident Cardiovascular Disease and All-Cause Mortality in Type 1 Diabetes"],"prefix":"10.2337","volume":"59","author":[{"given":"Johanna W.M.","family":"Nin","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, Maastricht University Medical Centre, Maastricht, the Netherlands;"},{"name":"Cardiovascular Research Institute Maastricht (CARIM), Maastricht University Medical Centre, Maastricht, the Netherlands;"},{"name":"Care and Public Health Research Institute (CAPHRI), Maastricht University Medical Centre, Maastricht, the Netherlands;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anders","family":"Jorsal","sequence":"additional","affiliation":[{"name":"Steno Diabetes Center, Gentofte, Denmark;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabel","family":"Ferreira","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Maastricht University Medical Centre, Maastricht, the Netherlands;"},{"name":"Cardiovascular Research Institute Maastricht (CARIM), Maastricht University Medical Centre, Maastricht, the Netherlands;"},{"name":"Care and Public Health Research Institute (CAPHRI), Maastricht University Medical Centre, Maastricht, the Netherlands;"},{"name":"Department of Clinical Epidemiology and Medical Technology Assessment, Maastricht University Medical Centre, Maastricht, the Netherlands;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Casper G.","family":"Schalkwijk","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Maastricht University Medical Centre, Maastricht, the Netherlands;"},{"name":"Cardiovascular Research Institute Maastricht (CARIM), Maastricht University Medical Centre, Maastricht, the Netherlands;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin H.","family":"Prins","sequence":"additional","affiliation":[{"name":"Care and Public Health Research Institute (CAPHRI), Maastricht University Medical Centre, Maastricht, the Netherlands;"},{"name":"Department of Clinical Epidemiology and Medical Technology Assessment, Maastricht University Medical Centre, Maastricht, the Netherlands;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans-Henrik","family":"Parving","sequence":"additional","affiliation":[{"name":"Department of Medical Endocrinology, Rigshospitalet, Copenhagen, Denmark;"},{"name":"Faculty of Health Science, Aarhus University, Aarhus, Denmark."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lise","family":"Tarnow","sequence":"additional","affiliation":[{"name":"Steno Diabetes Center, Gentofte, Denmark;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Rossing","sequence":"additional","affiliation":[{"name":"Steno Diabetes Center, Gentofte, Denmark;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Coen D.A.","family":"Stehouwer","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Maastricht University Medical Centre, Maastricht, the Netherlands;"},{"name":"Cardiovascular Research Institute Maastricht (CARIM), Maastricht University Medical Centre, Maastricht, the Netherlands;"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1167","published-online":{"date-parts":[[2010,6,3]]},"reference":[{"key":"2022031208554415700_B1","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1042\/CS20080494","article-title":"RAGE: a novel biological and genetic marker for vascular disease","volume":"116","author":"Kalea","year":"2009","journal-title":"Clin Sci (Lond)"},{"key":"2022031208554415700_B2","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1161\/01.CIR.0000086014.80477.0D","article-title":"The receptor RAGE as a progression factor amplifying arachidonate-dependent inflammatory and proteolytic response in human atherosclerotic plaques: role of glycemic control","volume":"108","author":"Cipollone","year":"2003","journal-title":"Circulation"},{"key":"2022031208554415700_B3","doi-asserted-by":"crossref","first-page":"31740","DOI":"10.1074\/jbc.274.44.31740","article-title":"N(epsilon)-(carboxymethyl) lysine adducts of proteins are ligands for receptor for advanced glycation end products that activate cell signaling pathways and modulate gene expression","volume":"274","author":"Kislinger","year":"1999","journal-title":"J Biol Chem"},{"key":"2022031208554415700_B4","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1172\/JCI32703","article-title":"Vascular and inflammatory stresses mediate atherosclerosis via RAGE and its ligands in apoE-\/- mice","volume":"118","author":"Harja","year":"2008","journal-title":"J Clin Invest"},{"key":"2022031208554415700_B5","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1161\/hc0702.104183","article-title":"Advanced glycation end products activate endothelium through signal-transduction receptor RAGE: a mechanism for amplification of inflammatory responses","volume":"105","author":"Basta","year":"2002","journal-title":"Circulation"},{"key":"2022031208554415700_B6","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1016\/S0002-9440(10)63909-0","article-title":"RAGE drives the development of glomerulosclerosis and implicates podocyte activation in the pathogenesis of diabetic nephropathy","volume":"162","author":"Wendt","year":"2003","journal-title":"Am J Pathol"},{"key":"2022031208554415700_B7","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1007\/s00125-009-1263-5","article-title":"Levels of soluble receptor for AGE are cross-sectionally associated with cardiovascular disease in type 1 diabetes, and this association is partially mediated by endothelial and renal dysfunction and by low-grade inflammation: the EURODIAB Prospective Complications Study","volume":"52","author":"Nin","year":"2009","journal-title":"Diabetologia"},{"key":"2022031208554415700_B8","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1111\/j.1523-1755.2005.00521.x","article-title":"Improved prognosis in type 1 diabetic patients with nephropathy: a prospective follow-up study","volume":"68","author":"Astrup","year":"2005","journal-title":"Kidney Int"},{"key":"2022031208554415700_B9","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.2337\/dc07-1960","article-title":"Markers of endothelial dysfunction and inflammation in type 1 diabetic patients with or without diabetic nephropathy followed for 10 years: association with mortality and decline of glomerular filtration rate","volume":"31","author":"Astrup","year":"2008","journal-title":"Diabetes Care"},{"key":"2022031208554415700_B10","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1002\/dmrr.690","article-title":"Elevation of soluble form of receptor for advanced glycation end products (sRAGE) in diabetic subjects with coronary artery disease","volume":"23","author":"Nakamura","year":"2007","journal-title":"Diabete Metab Res Rev"},{"key":"2022031208554415700_B11","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1016\/j.atherosclerosis.2008.12.016","article-title":"Increased serum HMGB1 level is associated with coronary artery disease in nondiabetic and type 2 diabetic patients","volume":"205","author":"Yan","year":"2009","journal-title":"Atherosclerosis"},{"key":"2022031208554415700_B12","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/1475-2840-6-9","article-title":"Soluble RAGE but not endogenous secretory RAGE is associated with albuminuria in patients with type 2 diabetes","volume":"6","author":"Humpert","year":"2007","journal-title":"Cardiovasc Diabetol"},{"key":"2022031208554415700_B13","doi-asserted-by":"crossref","first-page":"2756","DOI":"10.1007\/s00125-006-0394-1","article-title":"Association between serum levels of soluble receptor for advanced glycation end products and circulating advanced glycation end products in type 2 diabetes","volume":"49","author":"Tan","year":"2006","journal-title":"Diabetologia"},{"key":"2022031208554415700_B14","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.mvr.2007.09.004","article-title":"Serum levels of soluble form of receptor for advanced glycation end products (sRAGE) are positively associated with circulating AGEs and soluble form of VCAM-1 in patients with type 2 diabetes","volume":"76","author":"Nakamura","year":"2008","journal-title":"Microvasc Res"},{"key":"2022031208554415700_B15","doi-asserted-by":"crossref","first-page":"185","DOI":"10.2119\/2006-00090.Nakamura","article-title":"Serum levels of sRAGE, the soluble form of receptor for advanced glycation end products, are associated with inflammatory markers in patients with type 2 diabetes","volume":"13","author":"Nakamura","year":"2007","journal-title":"Mol Med"},{"key":"2022031208554415700_B16","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1042\/bj20021371","article-title":"Novel splice variants of the receptor for advanced glycation end-products expressed in human vascular endothelial cells and pericytes, and their putative roles in diabetes-induced vascular injury","volume":"370","author":"Yonekura","year":"2003","journal-title":"Biochem J"},{"key":"2022031208554415700_B17","doi-asserted-by":"crossref","first-page":"3716","DOI":"10.1096\/fj.08-109033","article-title":"A soluble form of the receptor for advanced glycation endproducts (RAGE) is produced by proteolytic cleavage of the membrane-bound form by the sheddase a disintegrin and metalloprotease 10 (ADAM10)","volume":"22","author":"Raucci","year":"2008","journal-title":"FASEB J"},{"key":"2022031208554415700_B18","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1016\/j.clinbiochem.2009.04.017","article-title":"Decreased serum esRAGE level is associated with angiographically determined coronary plaque progression in diabetic patients","volume":"42","author":"Peng","year":"2009","journal-title":"Clin Biochem"},{"key":"2022031208554415700_B19","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1016\/j.atherosclerosis.2008.12.045","article-title":"Increased glycated albumin and decreased esRAGE levels are related to angiographic severity and extent of coronary artery disease in patients with type 2 diabetes","volume":"206","author":"Lu","year":"2009","journal-title":"Atherosclerosis"},{"key":"2022031208554415700_B20","doi-asserted-by":"crossref","first-page":"2587","DOI":"10.1161\/01.ATV.0000190660.32863.cd","article-title":"Plasma level of endogenous secretory RAGE is associated with components of the metabolic syndrome and atherosclerosis","volume":"25","author":"Koyama","year":"2005","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"2022031208554415700_B21","doi-asserted-by":"crossref","first-page":"190","DOI":"10.3132\/dvdr.2008.031","article-title":"Endogenous secretory RAGE but not soluble RAGE is associated with carotid atherosclerosis in type 1 diabetes patients","volume":"5","author":"Katakami","year":"2008","journal-title":"Diab Vasc Dis Res"},{"key":"2022031208554415700_B22","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/j.atherosclerosis.2008.08.026","article-title":"Serum endogenous secretory RAGE level is an independent risk factor for the progression of carotid atherosclerosis in type 1 diabetes","volume":"204","author":"Katakami","year":"2009","journal-title":"Atherosclerosis"},{"key":"2022031208554415700_B23","doi-asserted-by":"crossref","first-page":"2716","DOI":"10.2337\/diacare.28.11.2716","article-title":"Decreased endogenous secretory advanced glycation end product receptor in type 1 diabetic patients: its possible association with diabetic vascular complications","volume":"28","author":"Katakami","year":"2005","journal-title":"Diabetes Care"},{"key":"2022031208554415700_B24","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1053\/j.ajkd.2008.06.018","article-title":"Advanced glycation end products and their circulating receptors and level of kidney function in older community-dwelling women","volume":"53","author":"Semba","year":"2009","journal-title":"Am J Kidney Dis"}],"container-title":["Diabetes"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.org\/diabetes\/diabetes\/article-pdf\/59\/8\/2027\/397236\/zdb00810002027.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/diabetesjournals.org\/diabetes\/article-pdf\/59\/8\/2027\/397236\/zdb00810002027.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,2]],"date-time":"2022-11-02T16:21:20Z","timestamp":1667406080000},"score":1,"resource":{"primary":{"URL":"https:\/\/diabetesjournals.org\/diabetes\/article\/59\/8\/2027\/14579\/Higher-Plasma-Soluble-Receptor-for-Advanced"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,6,3]]},"references-count":24,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2010,6,3]]},"published-print":{"date-parts":[[2010,8,1]]}},"URL":"https:\/\/doi.org\/10.2337\/db09-1509","relation":{},"ISSN":["0012-1797","1939-327X"],"issn-type":[{"value":"0012-1797","type":"print"},{"value":"1939-327X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,6,3]]}}}